Clinical Trials on Non-Small Cell Lung Cancer NSCLC

Total 7981 results

University of Pittsburgh
Bristol-Myers Squibb

Completed

Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC

Non Small Cell Lung Cancer (NSCLC)

United States
R-Pharm

Completed

Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

Japan
Dana-Farber Cancer Institute
Brigham and Women's Hospital

Terminated

Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer

NSCLC | Lung Cancer | Non-small Cell Lung Cancer

United States
Merck KGaA, Darmstadt, Germany

Completed

Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC) (NEXT)

Non-Small Cell Lung Cancer (NSCLC)

Germany
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer (NSCLC)

United States, Canada, France, Singapore, Taiwan
Fatebenefratelli and Ophthalmic Hospital
Niguarda Hospital; Mario Negri Institute for Pharmacological Research

Unknown

Tarceva Italian Lung Optimization tRial (TAILOR)

Non Small Cell Lung Cancer (NSCLC)

Italy
NovoCure Ltd.

Completed

NovoTTF-100L in Combination With Pemetrexed (Alimta®) for Advanced Non-small Cell Lung Cancer

NSCLC | Non-small Cell Lung Cancer

Switzerland
Simcere Pharmaceutical Co., Ltd

Unknown

A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC) (NSCLC)

Non-small Cell Lung Cancer (NSCLC)

China
University Hospital, Essen

Recruiting

Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients (NEOpredict)

NSCLC, Stage I | NSCLC Stage II | NSCLC, Stage IIIA

Belgium, Germany, Netherlands
Second Affiliated Hospital, School of Medicine,...
Tongji Hospital; Qilu Hospital of Shandong University; First Hospital of China... and other collaborators

Recruiting

A Study With Pembrolizumab for Non-small Cell Lung Cancer (NSCLC)

Pembrolizumab | Non-small-lung-cell Cancer, NSCLC

China
Beijing Haidian Hospital
307 Hospital of PLA; Peking University People's Hospital; 309th Hospital of Chinese...

Recruiting

The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation

Non-small Cell Lung Cancer(NSCLC)

China
Johns Hopkins University
AstraZeneca

Enrolling by invitation

ROSE for Improved Molecular Marker Testing Via EBUS (ROSE/NoROSE)

Non-small Cell Lung Cancer (NSCLC)

United States
Albert Einstein College of Medicine
Montefiore Medical Center

Active, not recruiting

The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial. (SPRINT)

Non-small Cell Lung Cancer, NSCLC

United States
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Active, not recruiting

Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors. (PEOPLE)

Non Small Cell Lung Cancer (NSCLC)

Italy
Abramson Cancer Center of the University of Pennsylvania

Terminated

Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy

Non-Small Cell Lung Cancer (NSCLC)

United States
AstraZeneca

Approved for marketing

Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment

Non Small Cell Lung Cancer (NSCLC)

Taiwan, Thailand, Turkey, Brazil, Philippines, Russian Federation, Romania, Austria, Hungary, Bulgaria, Latvia, India, Argentina, Australia, Estonia, Malaysia, Mexico, Singapore, South Africa
Dr Joanne CHIU

Recruiting

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

ALK Gene Rearrangement Positive | EGF-R Positive Non-Small Cell Lung Cancer | EGFR Activating Mutation | Nsclc | ROS1 Gene Rearrangement | ROS1 Positive NSCLC - Reactive Oxygen Species 1 Positive Non-Small Cell Lung Cancer

Hong Kong
Sanofi

Active, not recruiting

Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC (CARMEN-LC05)

Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Spain, United States, Brazil, Chile, Czechia, France, Hungary, Israel
TheRas, Inc., d/b/a BridgeBio Oncology Therapeutics

Recruiting

Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

NSCLC | Metastatic Lung Cancer | Non-small Cell Lung Cancer | Advanced Lung Carcinoma | Metastatic Non-Small Cell Lung Cancer | KRAS G12C

United States, Australia
Amgen

No longer available

Expanded Access of Sotorasib

Non Small-cell Lung Cancer | Locally Advanced Unresectable NSCLC | Locally Advanced Metastatic NSCLC

United States, Taiwan, Israel, Saudi Arabia, Brazil, Argentina
Swiss Group for Clinical Cancer Research

Recruiting

Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients (salVage)

Non-small Cell Lung Cancer (NSCLC) | Stage IV

Switzerland
Suzhou Puhe Pharmaceutical Technology Co., LTD

Not yet recruiting

YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

China
Takeda

Active, not recruiting

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

United States, Spain, France, Korea, Republic of, Hong Kong, Australia, Taiwan, United Kingdom, Canada, Turkey, Italy, China, Germany, Japan, Austria, Belgium, Greece, Israel, Netherlands, Portugal, Russian Federation, Singapore, Sw... and more
Ivy Life Sciences, Co., Ltd
Taipei Veterans General Hospital, Taiwan; Tri-Service General Hospital

Completed

A Study to Evaluate the Safety and Efficacy of Ex Vivo Expanded Autologous Immune Killer Cells (IKC) in Stage IV Non-small Cell Lung Cancer (NSCLC) in Patients Who Failed Chemotherapy or Target Therapy (IVY03)

Non-small Cell Lung Cancer (NSCLC) Stage IV

Taiwan
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)

ROS1-positive Non-Small Cell Lung Cancer (NSCLC)

China
University of California, Davis
Novartis Pharmaceuticals

Completed

Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors

Solid Tumors | Non-Small Cell Lung Cancer (NSCLC)

United States
Hoffmann-La Roche

Recruiting

A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy (SKYSCRAPER-15)

Non-small Cell Lung Cancer (NSCLC)

Korea, Republic of, United States, China, Japan, Australia, Taiwan, Brazil, Argentina, Hong Kong
Servier Bio-Innovation LLC
Regeneron Pharmaceuticals; Institut de Recherches Internationales Servier

Not yet recruiting

Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC)

Hong Kong, United States, Australia
Jinming Yu

Recruiting

Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

China
Pingping Song

Not yet recruiting

Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer(NSCLC)

China
Jinming Yu

Recruiting

WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC

Non-small Cell Lung Cancer (NSCLC)

China
Shanghai Miracogen Inc.

Not yet recruiting

A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).

Non-small- Cell Lung Cancer (NSCLC)

China
BeiGene

Recruiting

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

NSCLC | Non-small Cell Lung Cancer

Japan, United States, France, Mexico, Germany, Argentina, Brazil, Korea, Republic of, Turkey
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Recruiting

HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, Taiwan, Japan
Daiichi Sankyo

Recruiting

HER3-DXd in Metastatic or Unresectable Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, Spain, Japan, Netherlands, Taiwan
Hoffmann-La Roche

Active, not recruiting

A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer (SKYSCRAPER-06)

Non-small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, Canada, Belgium, China, Denmark, Spain, Thailand, United Kingdom, Taiwan, Brazil, Germany, Mexico, Italy, Switzerland, Hong Kong, Japan, France, Turkey, New Zealand, Poland
Novartis Pharmaceuticals

Active, not recruiting

Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation (GeoMETry-C)

Non-Small Cell Lung Cancer (NSCLC)

China
AstraZeneca

Active, not recruiting

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) (ORION)

Non-small Cell Lung Cancer NSCLC

United Kingdom, Belgium, United States, Korea, Republic of, Hungary, Japan, Russian Federation, Poland, Ukraine, India, Mexico, Netherlands
University of Texas Southwestern Medical Center
AstraZeneca

Active, not recruiting

Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC

Non-small Cell Lung Cancer (NSCLC)

United States
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%

Non-small Cell Lung Cancer (NSCLC)

Japan, Germany, Spain, Italy, France, Thailand, Belgium, Netherlands, India, Malaysia, Taiwan, Australia, Canada, Czechia, Greece, Hong Kong
Abramson Cancer Center at Penn Medicine

Completed

Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer

Oligometastatic Non-small Cell Lung Cancer (NSCLC)

United States
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

China
Incyte Corporation

Completed

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration (FIGHT-210)

Non-Small Cell Lung Cancer (NSCLC)

Spain, United States, Italy, Germany, France
Takeda

Completed

A Spanish Medical Record Review of Clinical Characteristics and Outcomes in Non-small Cell Lung Cancer Participants With EGFR Exon 20 Insertion (ermEX-20)

Non-small Cell Lung Cancer (NSCLC)

Spain
G1 Therapeutics, Inc.

Terminated

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4) (PRESERVE 4)

NSCLC | Lung Cancer | Metastatic Non-Small Cell Lung Cancer

United States
Takeda

Completed

A Chart Review Study of Adults With Advanced NSCLC (EXTRACT)

Non-small Cell Lung Cancer (NSCLC)

Hong Kong, France, Canada
Albert Einstein College of Medicine
Celldex Therapeutics

Completed

FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer (FLT3)

Non-small Cell Lung Cancer (NSCLC)

United States
Daiichi Sankyo, Inc.

Terminated

DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

Taiwan
Hoffmann-La Roche

Withdrawn

A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)
Novartis Pharmaceuticals

No longer available

Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC

Non-small Cell Lung Cancer (NSCLC)

United States, Argentina, Korea, Republic of, Hong Kong, Thailand, Mexico, Jordan, Colombia, India, Philippines

Clinical Trials on Non-Small Cell Lung Cancer NSCLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations